DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Patent 7,396,341 protects COMBIVENT RESPIMAT, STRIVERDI RESPIMAT, SPIRIVA RESPIMAT, and STIOLTO RESPIMAT, and is included in four NDAs.
Protection for SPIRIVA RESPIMAT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-one patent family members in twenty-seven countries.
Summary for Patent: 7,396,341
|Title:||Blocking device for a locking stressing mechanism having a spring-actuated output drive device|
|Abstract:||A locking-stressing-mechanism with spring-actuated output drive and a counter with which an apparatus of this kind is fitted, accommodated in a two part housing the two parts of which are mounted to be rotatable relative to each other, can be blocked by means of a pre-stressed leaf spring. The leaf spring is initially accommodated in a recess in the wall of one housing part. As soon as the permitted number of actuations has been reached a push rod pushes the leaf spring out of its resting position. The leaf spring then jumps into a recess in the wall of the other housing part and the two housing parts can no longer be rotated relative to each other. The push rod may be mounted on the pointer of the counter. This blocking device can only be overcome by the application of a force which is sufficient to destroy the device. The device is suitable for blocking a high pressure atomiser or a needleless injector with which a fluid is atomised to form an aerosol or a fluid is injected into a biological tissue.|
|Inventor(s):||Schyra; Michael (Wuppertal, DE), Wachtel; Herbert (Bingen, DE)|
|Assignee:||Boehringer Ingelheim International GmbH (Ingelheim, DE)|
Patent Claim Types:|
see list of patent claims
|Use; Device; Dosage form;|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use||Submissiondate|
|Boehringer Ingelheim||COMBIVENT RESPIMAT||albuterol sulfate; ipratropium bromide||SPRAY, METERED;INHALATION||021747-001||Oct 7, 2011||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|Boehringer Ingelheim||STRIVERDI RESPIMAT||olodaterol hydrochloride||SPRAY, METERED;INHALATION||203108-001||Jul 31, 2014||RX||Yes||Yes||Start Trial||Start Trial||Y||TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA||Start Trial|
|Boehringer Ingelheim||SPIRIVA RESPIMAT||tiotropium bromide||SPRAY, METERED;INHALATION||021936-002||Sep 15, 2015||RX||Yes||No||Start Trial||Start Trial||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Patented / Exclusive Use||>Submissiondate|
Foreign Priority and PCT Information for Patent: 7,396,341
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Germany||102 39 443||Aug 28, 2002|
|Country||Patent Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|>Country||>Patent Number||>Estimated Expiration||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration|